Evofem Biosciences to Present at Aegis Virtual Conference on Wednesday, February 23, 2022

Evofem Biosciences to Present at Aegis Virtual Conference on Wednesday, February 23, 2022

PR Newswire

SAN DIEGO, Feb. 8, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will present at the Aegis Virtual Conference as follows:

Date:

Wednesday, February 23, 2022 

Time:

4:30 p.m. ET (1:30 p.m. PT)

Access Webcast:

https://evofem.investorroom.com/Aegis2022 or

https://us02web.zoom.us/j/86168915443 

Add to Calendar:

iCalendar (.ics) file

About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia and gonorrhea). The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
[email protected]
Mobile: (917) 673-5775

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-aegis-virtual-conference-on-wednesday-february-23-2022-301477311.html

SOURCE Evofem Biosciences, Inc.

Copyright CNW Group 2022